文献速递消化道肿瘤放疗姑息放疗与转移瘤

临界可切除/局部晚期胰腺癌患者术前化疗联合立体定向体部放疗后的失败模式

Patterns of Failure in Patients With Borderline Resectable/Locally Advanced Pancreatic Cancer After Preoperative Chemotherapy and Stereotactic Body Radiation Therapy.
PubMed 文献 · Adv Radiat Oncol · 2024-02-12

该单机构回顾性研究纳入2017年9月至2022年1月接受术前化疗联合33 Gy/5次SBRT后手术切除的18例临界可切除/局部晚期胰腺癌患者,中位随访30个月,R0切除率94%,中位总生存42个月,远处进展为主要失败模式(61%),局部或区域复发28%。

要点

  • 术前化疗联合非剂量递增SBRT后手术切除的BR/LAPC患者局部控制率和R0切除率均优异。
  • 远处复发是主要失败部位,孤立性局部区域复发发生率较低。
  • 尚需进一步研究确定理想治疗体积及可能从剂量递增中获益的患者。

核心结论

  • 术前化疗联合非剂量递增SBRT在手术切除的BR/LAPC患者中局部控制率和切缘阴性切除率均优异,远处复发是主要失败部位,孤立性局部区域复发发生率较低。
  • 作者认为需要进一步研究以确定理想治疗体积及可能从剂量递增中获益的患者。

研究设计与样本

  • 单机构回顾性研究,连续纳入2017年9月至2022年1月接受术前化疗和SBRT后手术切除的BR/LAPC患者。
  • 共纳入18例患者(12例临界可切除胰腺癌,6例局部晚期胰腺癌),中位年龄69岁(范围41-84岁)。
  • SBRT剂量为33 Gy分5次照射。
  • 采用Kaplan-Meier法计算总生存和无进展生存。

主要发现

  • 中位随访30个月(范围13-59个月),17例(94%)实现R0切除,13例(72%)接受血管重建。
  • 中位总生存42个月(范围13-59个月),中位无进展生存23个月(范围1-45个月)。
  • 61%(11/18)的患者在随访期间任何时间点出现进展。
  • 在出现复发的患者中,27%(3/11)以局部进展作为首次复发的组成部分,100%(11/11)以远处进展作为首次复发的组成部分。
  • 在随访期间任何时间点的所有复发中,28%(5/18)的患者出现局部或区域复发,61%(11/18)出现远处进展。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The role of preoperative stereotactic body radiation therapy (SBRT) in pancreatic cancer is controversial, and questions regarding the optimal dose and radiation treatment field remain. To better inform future investigations of SBRT dose and radiation fields, we evaluated the patterns of failure in patients with borderline resectable/locally advanced pancreatic cancer (BR/LAPC) after preoperative chemotherapy and SBRT in patients who underwent surgical resection. METHODS AND MATERIALS: We performed a single-institution retrospective review of consecutive patients treated from September 2017 to January 2022 with BR/LAPC. Patients who underwent preoperative chemotherapy and SBRT followed by surgical resection were reviewed. SBRT was delivered to a dose of 33 Gy in 5 fractions. Kaplan-Meier overall survival and progression-free survival estimates were calculated. RESULTS: In total, 18 patients (12 BRPC, 6 LAPC) were included. Median age was 69 years (range 41-84 years). Median follow-up was 30 months (range 13-59 months). Seventeen patients (94%) had a R0 resection and 13 (72%) underwent vascular reconstruction. Median overall survival and progression-free survival was 42 months (range 13-59 months) and 23 months (range 1-45 months), respectively. In total, 61% (11/18) patients experienced progression at any point during follow-up. Of the patients who experienced recurrence, 27% (3/11) experienced local progression as component of their first recurrence, whereas 100% (11/11) experienced distant progression as a component of their first recurrence. When examining all recurrences that occurred at any point in follow-up, 28% (5/18) of patients experienced local or locoregional recurrence and 61% (11/18) experienced distant progression. CONCLUSIONS: Local control and margin negative resection rates were excellent with preoperative chemotherapy and nondose-escalated SBRT in surgically resected patients with BR/LAPC. Distant recurrence was the predominant site of failure with lower incidences of isolated locoregional recurrences. Additional research is needed to determine the ideal treatment volume and patients who may benefit from dose escalation.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Chung EM, Lu DJ, Nguyen AT, et al. Patterns of Failure in Patients With Borderline Resectable/Locally Advanced Pancreatic Cancer After Preoperative Chemotherapy and Stereotactic Body Radiation Therapy. Adv Radiat Oncol. 2024. PMID: 38550374. doi:10.1016/j.adro.2024.101471

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。